转移性结直肠癌靶向治疗中的关键分子  

Key molecules in targeted therapies for metastatic colorectal cancer

作　　者：李慧明[1] 余英豪[1] 

机构地区：[1]中国人民解放军南京军区福州总医院病理科,福建省福州市350025

出　　处：《世界华人消化杂志》2014年第3期350-358,共9页World Chinese Journal of Digestology

摘　　要：结直肠癌(colorectal cancer,CRC)是世界上常见的恶性肿瘤之一,而转移性结直肠癌(metastatic colorectal cancer,mCRC)患者的生存率明显下降.近年来,随着西妥昔单抗、贝伐单抗等分子靶向治疗药物的应用,mCRC患者的生存期得到了显著改善.但我们对于这些分子靶点在结直肠癌中的确切作用,以及肿瘤生长对这些分子的依赖性认识并不充分.因此,对于如何选择患者以及预测疗效仍有疑问.本文对mCRC靶向治疗中血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)、KRAS、BRAF、磷脂酰肌醇3激酶(phosphatidylinositol 3 kinase,PI3K)等关键分子的生物学特性及其突变状态与治疗的相关性,及可能的预测/预后标志物进行综述.Colorectal cancer （CRC） is one of the most com- mon malignant tumors, and the survival rate of metastatic CRC （mCRC） decreased obviously compared with non-metastatic CRC. In recent years, the application of molecular targeted drugs, such as cetuximab and bevacizumab, has significantly improved the survival of mCRC patients. However, the precise role of the mo- lecular targets in colorectal cancer, as well as the dependence of tumor growth on these molecules are not fully understood. Therefore, patient selection and prediction of treatment effects re- main problematic＇. In this paper, we will review the biological characteristics of key molecules in targeted therapies for mCRC, such as vascular endothelial growth factor receptor （VEGFR）, KRAS, BRAF and phosphatidylinositol 3 kinase （PI3K）, the correlation between their mutational status and treatment, and the potential predic- tive/prognostic biomarkers.

关 键 词：MCRC 靶向治疗 分子标志物 血管内皮生长因子受体 KRAS TOPK 

分 类 号：R735.3[医药卫生—肿瘤]